在乳腺癌治疗中使用循环素依赖性激酶4和6抑制剂
Zhengfei Guo1, Richard W Dong2, Yusheng Wu1
1TYK Medicines, Inc., Huzhou, Zhejiang, 313100, China.
Oncogene
|April 8, 2025
概括
向循环素依赖性激酶4和6 (CDK4/6) 在乳腺癌治疗中显示出有前途. 本综述探讨了抗性机制和组合策略,以克服对CDK4/6抑制剂的获得性耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是全球癌症死亡的主要原因,尤其是女性.
- 异常的环林依赖激酶4和6 (CDK4/6) 路径激活驱动着不受控制的乳腺癌细胞增殖.
- CDK4/6抑制剂已被批准用于激素受体阳性,HER2-阴性转移性乳腺癌,显示出显著的成功.
研究的目的:
- 系统地审查乳腺癌中对CDK4/6抑制剂获得性耐药性的机制.
- 分析组合策略,以提高CDK4/6抑制剂的疗效.
主要方法:
- 对CDK4/6抑制剂耐药性的现有文献进行系统审查.
- 对细胞周期特异性和细胞周期非特异性抵抗机制的分析.
- 对组合疗法的临床前和临床数据的评估.
主要成果:
- 确定了各种机制,有助于获得对CDK4/6抑制剂的耐药性.
- 突出了将CDK4/6抑制剂与其他向药物的结合潜力.
- 证明了组合策略可以克服耐药性并改善治疗结果.
结论:
- 了解抵抗机制对于改善CDK4/6抑制剂治疗至关重要.
- 组合策略提供了一个有前途的方法来增强CDK4/6抑制剂的临床应用.
- 对组合疗法的进一步研究可能会提高乳腺癌患者的生存率.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


